NCT03774056View on ClinicalTrials.gov

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

September 26, 2018

Study Completion Date

August 28, 2019

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

HC-1119

oral

Trial Locations (1)

610041

Hinova Pharmaceuticals Inc., Chengdu

Sponsors
All Listed Sponsors
collaborator

West China Hospital

OTHER

lead

Hinova Pharmaceuticals Inc.

INDUSTRY

NCT03774056 - A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. | Biotech Hunter | Biotech Hunter